| Bioactivity | Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects[1]. |
| In Vivo | Vanucizumab (20mg /kg;i.p。每周1次;6周) 显示肿瘤生长抑制和诱导肿瘤停滞[2]。 Animal Model: |
| Name | Vanucizumab |
| CAS | 1448221-05-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Manuel Hidalgo, et al. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. [2]. Wolfgang Schaefer, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. |